Calidi Biotherapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Calidi Biotherapeutics, Inc. · CLDWW
原披露日期:;精度:秒。
来源:SEC(SEC EDGAR 8-K)。
查看原始披露 ↗原文限定:This press release may contain forward-looking statements for purposes of the “safe harbor” provisions under the United States Private Securities Litigation Reform Act of 1995. Terms such as “anticipates,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predicts,” “project,” “should,” “towards,” “would” as well as similar terms, are forward-looking in nature, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, the Company’s plans strategies, priorities and key operational initiatives for fiscal year 2026 and 2027, including the Company’s plan to dose the first patient in the second half of 2027, statements concerning key milestones, including certain pre-clinical data, planned clinical trials, and statements relating to the safety and efficacy of Calidi’s therapeutic candidates in development. Any forward-looking statements contained in this discussion are based on Calidi’s current expectations and beliefs concerning future developments and their potential effects and are subject to multiple risks and uncertainties that could cause
原文限定:(unaudited)
标题保留原文的计划、申请、条件、初步结果及否定状态,以原文为准。本站核验来源归属、证券身份及披露时间,不保证公司陈述或投资价值。
核验记录与处理时间
来源原始时间字段:2026-11-13T21:35:14.000Z;日期依据:SEC accepted filing time (Atom and index checked); calendar date is America/New_York; not an inferred press-release time。
采集层首次发现:2026-11-13T21:45:30.398Z;事件路径观察:2026-11-13T21:46:01.283Z。
处理开始:2026-11-14T00:15:50.214Z;处理完成:2026-11-14T00:15:53.231Z;首次资格通过:2026-11-14T00:15:53.231Z;首次公开:2026-11-14T00:15:53.231Z。
公开模式:natural_new;处理方式:automatic;规则版本:sec_company_events_v3_filed_release;自然时槽:2026-11-14T00:15:23.513Z。
保留原始披露及首次时间,重新展示不重写发布时间。
身份核验记录:2026-11-14T00:15:51.529Z;来源核验记录:2026-11-14T00:15:51.529Z。